Behavioural and biochemical effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155) on the central nervous system

British Journal of Pharmacology
R Laverty, K M Taylor


1. St 155 (2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride) (0.1-2.5 mg/kg subcutaneously) in rats prolonged chloral hydrate sleeping time, inhibited exploratory activity, reduced rotarod performance and pain-induced aggression; in rats and guinea-pigs conditioned avoidance behaviour was inhibited.2. In most experiments St 155 was 5-7 times more potent than chlorpromazine on a weight basis. In white rats St 155 and chlorpromazine were equi-effective in inhibiting conditioned avoidance behaviour. St 155 was relatively less active than chlorpromazine in lowering body temperature.3. Chronic treatment with St 155 resulted in a reduction of its hypotensive and sedative effects and caused irritability and spontaneous episodes of severe fighting in white rats.4. St 155, at doses causing similar conditioned avoidance response inhibition, produced a significant increase in noradrenaline concentration in all brain regions except the striate. Radioisotope studies indicate an increase in noradrenaline storage without significant changes in metabolism.


Nov 1, 1967·Clinical Pharmacology and Therapeutics·M DavidovF A Finnerty
Jan 1, 1967·Psychopharmacologia·A Randrup, I Munkvad
Jul 1, 1967·The Journal of Clinical Pharmacology and the Journal of New Drugs·G M SimpsonT P Watts
Feb 1, 1966·British Journal of Pharmacology and Chemotherapy·A V JuorioT Trajkov
Feb 1, 1957·British Journal of Psychology·P L BROADHURST
Mar 14, 1957·Annals of the New York Academy of Sciences·L COOK, E WEIDLEY
Jun 1, 1957·British Journal of Pharmacology and Chemotherapy·F N FASTIERH WAAL
Sep 13, 1958·Nature·F H SMIRK, W H HALL
Aug 1, 1962·British Journal of Pharmacology and Chemotherapy·G W ASHCROFT, D F SHARMAN
Oct 1, 1962·Journal of the Experimental Analysis of Behavior·R E ULRICH, N H AZRIN
Jan 1, 1964·Journal of the Experimental Analysis of Behavior·N H AZRIND G NORMAN
Dec 24, 1966·Nature·P B BradleyG L Avanzino

❮ Previous
Next ❯


Jan 1, 1972·Psychopharmacologia·R N Hughes
Aug 24, 1978·Naunyn-Schmiedeberg's Archives of Pharmacology·G Paalzow
Jan 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·K IshiiR Kato
May 17, 1978·European Journal of Clinical Pharmacology·A KeränenJ Taskinen
Jan 1, 1981·Journal of Neural Transmission·R BaileyO Jenkins
Jan 1, 1988·Journal of Neural Transmission·E HårdA S Lindh
Jan 1, 1985·Journal of Neural Transmission·E MogilnickaA Czyrak
Jan 1, 1982·Journal of Neural Transmission·C Spyraki, H C Fibiger
Jan 1, 1980·Journal of Neural Transmission·U Strömbom, T H Svensson
Jan 1, 1975·Journal of Neural Transmission·U Strömbom
Jan 1, 1972·European Journal of Pharmacology·K M Taylor, R Laverty
May 15, 1977·European Journal of Pharmacology·H A TilsonJ P Buyniski
Oct 15, 1978·European Journal of Pharmacology·J C JuskevichD Whitehorn
Jan 5, 1981·European Journal of Pharmacology·P E McCleary, J D Leander
Jan 1, 1981·Neuropharmacology·M T LinY M Chen
Jul 1, 1978·Physiology & Behavior·J AtkinsonL Peters-Haefeli
Jan 1, 1978·Pharmacology, Biochemistry, and Behavior·J R McLeanL L Coughenour

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here